ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Resignation of Director.

On April 13, 2018, George Golumbeski, Ph.D. notified Acceleron Pharma Inc. (the “Company”) of his decision to resign from the Company's Board of Directors (the "Board") effective as of the Company's Annual Meeting of Stockholders on June 6, 2018. Dr. Golumbeski has served on the Board since 2011, and his resignation from the Board will be effective subsequent to his retirement from Celgene Corporation. The resignation of Dr. Golumbeski was not caused by any disagreement with the Company.


About ACCELERON PHARMA INC. (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.

An ad to help with our costs